Genes Involved in Lipid Disorders

• ClinicalTrials.gov Identifier: NCT02311335
• Recruitment Status: Recruiting
• First Posted: December 8, 2014
• Last Update Posted: October 1, 2019
• Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
• Information provided by (Responsible Party): National Institutes of Health Clinical Center (CC) ( National Heart, Lung, and Blood Institute (NHLBI) )

Tracking Information

• First Submitted Date: December 5, 2014
• First Posted Date: December 8, 2014
• Last Update Posted Date: October 1, 2019
• Actual Study Start Date: November 26, 2014
• Estimated Primary Completion Date: September 1, 2025 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: August 23, 2018)

Identify the gene(s) mutation (s) that causes rare cases of dyslipidemia [ Time Frame: Ongoing ]

Discovery data

• Original Primary Outcome Measures (submitted: December 5, 2014): Identify the gene(s) mutation (s) that causes rare cases of dyslipidemia [ Time Frame: 3 days to 50 years ]
• Change History: Complete list of historical versions of study NCT02311335 on ClinicalTrials.gov Archive Site
• Current Secondary Outcome Measures: Not Provided
• Original Secondary Outcome Measures: Not Provided
• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Genes Involved in Lipid Disorders
• Official Title: Genes Involved in Lipid Disorders

Brief Summary

Background:

- Genes are the instructions our body uses to function. Researchers can look for changes, or variants, in the genes. The goal of this study is to find new gene changes that lead to lipid disorders. Older research methods looked at one or a few genes at a time. Genomic sequencing looks at most of the genes at once. Genomic sequencing may find the cause researchers haven t been able to find from past methods.

Objectives:

- To better understand genetic causes of lipid disorders through genomic sequencing.

Eligibility:

- People age 2 and older with unusual lipid disorders, and their relatives.

Design:

• Participants will be screened with a physical exam and medical history. They will have blood taken. They may give a saliva sample.
• Based on the screening test, researchers will chose 3-5 family members to perform the genomic sequencing. The sequencing will be done on a sample of DNA collected during the blood draw and saliva sample.
• Participants may be invited to take part in other protocols that may involve imaging of their heart or blood vessels. They do not have to participate. If they do, they will sign a separate consent for those tests.
• If a participant s family member cannot travel to the NIH, the NIH documents and consent will be reviewed during a teleconference. A blood or sputum kit will be mailed to them.

• Detailed Description: The primary purpose of this discovery protocol is to identify new lipid genes from subjects with rare genetic lipids disorders. We will take advantage of the new technology of whole exome sequencing to find the cause of dyslipidemia that we haven t been able to find using past methods. We will work with geneticists to review the sequence data for unexpected gene changes (incidental findings) that do not explain the lipid disorder but gene changes that can cause medical disorders such as rare forms of cancer or heart disease. The opportunity to participate in the Clinical Center Genomics Opportunity (CCGO) program will enable us to take advantage of our expertise in other rare lipid disorders and translate this knowledge into new diagnostics and therapies, which is a key mission of the NIH.
• Study Type: Observational
• Study Design: Observational Model: Family-Based; Time Perspective: Prospective
• Target Follow-Up Duration: Not Provided
• Biospecimen: Not Provided
• Sampling Method: Non-Probability Sample
• Study Population: Entire population.
• Condition: Lipid Disorders
• Intervention: Not Provided

Study Groups/Cohorts

1

Dyslipidemia patients

Publications *

• Miller WG, Myers GL, Sakurabayashi I, Bachmann LM, Caudill SP, Dziekonski A, Edwards S, Kimberly MM, Korzun WJ, Leary ET, Nakajima K, Nakamura M, Nilsson G, Shamburek RD, Vetrovec GW, Warnick GR, Remaley AT. Seven direct methods for measuring HDL and LDL cholesterol compared with ultracentrifugation reference measurement procedures. Clin Chem. 2010 Jun;56(6):977-86. doi: 10.1373/clinchem.2009.142810. Epub 2010 Apr 8.
• Oliveira MJ, van Deventer HE, Bachmann LM, Warnick GR, Nakajima K, Nakamura M, Sakurabayashi I, Kimberly MM, Shamburek RD, Korzun WJ, Myers GL, Miller WG, Remaley AT. Evaluation of four different equations for calculating LDL-C with eight different direct HDL-C assays. Clin Chim Acta. 2013 Aug 23;423:135-40. doi: 10.1016/j.cca.2013.04.009. Epub 2013 Apr 27.
• Biesecker LG, Mullikin JC, Facio FM, Turner C, Cherukuri PF, Blakesley RW, Bouffard GG, Chines PS, Cruz P, Hansen NF, Teer JK, Maskeri B, Young AC; NISC Comparative Sequencing Program, Manolio TA, Wilson AF, Finkel T, Hwang P, Arai A, Remaley AT, Sachdev V, Shamburek R, Cannon RO, Green ED. The ClinSeq Project: piloting large-scale genome sequencing for research in genomic medicine. Genome Res. 2009 Sep;19(9):1665-74. doi: 10.1101/gr.092841.109. Epub 2009 Jul 14.

Recruitment Information

• Recruitment Status: Recruiting
• Estimated Enrollment (submitted: December 5, 2014): 250
• Original Estimated Enrollment: Same as current
• Estimated Study Completion Date: September 1, 2025
• Estimated Primary Completion Date: September 1, 2025 (Final data collection date for primary outcome measure)

Eligibility Criteria

• INCLUSION CRITERIA:

Index cases to be included are those with unusual dyslipidemia. Relatives of affected individuals may also be included as appropriate.

Child Index: greater than or equal to 2 years older

Adult Index: greater than or equal to18 years older

Child relatives (siblings, cousins): greater than or equal to 2 years older

Adult Relative: greater than or equal to18 years older

(Biological parent, aunt, uncle or grandparent)

EXCLUSION CRITERIA:

1. Inability or unwillingness to provide informed consent or assent
2. Prisoners or other institutionalized persons will not be allowed to participate.
3. Children <2 years of age.

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 2 Years to 99 Years (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Contacts

Contact: Robert D Shamburek, M.D.; (301) 496-3460; bobs@mail.nih.gov

• Listed Location Countries: United States

Administrative Information

• NCT Number: NCT02311335
• Other Study ID Numbers: 150024; 15-H-0024
• Has Data Monitoring Committee: Not Provided

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

• IPD Sharing Statement: Not Provided
• Responsible Party: National Institutes of Health Clinical Center (CC) ( National Heart, Lung, and Blood Institute (NHLBI) )
• Study Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
• Collaborators: Not Provided

Investigators

• Principal Investigator: Robert D Shamburek, M.D.; National Heart, Lung, and Blood Institute (NHLBI)

• PRS Account: National Institutes of Health Clinical Center (CC)
• Verification Date: August 19, 2019